The potential role of Nonsteroidal anti-inflammatory drugs (NSAIDS) in chemopreventation of cancer

Pakistan Journal of Medical Sciences

Volumn 19, Issue 1, 2003, Pages 13-17

  Saadat, Farshid ^a   Zomorodian, Kamiar ^a   Pezeshki, Mohammad ^a   Khorramizadeh, Mohammad Reza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apoptosis; Cancer; Matrix metalloproteinases; NSAIDs

Indexed keywords

DEXAMETHASONE; DICLOFENAC; GLUCOCORTICOID; MATRIX METALLOPROTEINASE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER PREVENTION; CELL DEATH; CHEMOPROPHYLAXIS; CYTOTOXICITY TEST; DOSE RESPONSE; FIBROSARCOMA; MOUSE; NICK END LABELING; NONHUMAN; ZYMOGRAPHY;

EID: 0037258629     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Vane JR. Inhibition of prostaglandin biosynthesis as a mechanism of action for aspirin like drugs. Nature, New Biol 1971; 231: 232-235.
2. Wallace JL. Mechanisms of nonsteroidal anti inflammatory drugs(NSAIDs) induced gastrointestinal damage-potential for development of gastrointestinal tract safe NSAIDs. Can J Physiol Pharmacol 1994; 72: 9717-9721.
3. Merlie JP, Fagan D, Mudd J, Needleman P. Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (Cyclooxygenase). J Biol Chem 1988; 263: 3550-3553.
4. Funk CD, Func LB, Kennedy ME, Pong AS, Fitzgerald GA. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression and gene chromosomal assignment. FASEB J 1991; 5: 2304-2312.
5. O'Neill PO, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and -2 in human tissues. FEBS Letter 1993; 330: 156-160.
6. Meade EA, Smith WL, Dewitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other nonsteroidal anti inflammatory drugs. J Biol Chem 1993; 268: 6610-6614.
7. Mitchell J.A., Akarasereenont P., Thiemermann C., Flower R.J., Vane J.R. Selectivity of nonsteroidal anti inflammatory drugs as inhibitors of constitutive and inducible cycloogygenase. Proc Natl Acad Sci, USA 1994; 90: 11693-11697.
8. O'Banion MK, Sadowski HB, Winn V, Young DA. A serum and glucocorticoid regulated 4 kb mRNA incodes a cycloogygenase related protein. J Biol Chem 1991; 266: 23261-23267.
9. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen responsive gene incoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci, USA 1991; 88: 2692-2696.
10. Hla T, Neilson K. Human cycloogynase type 2 cDNA. Proc Natl Acad Sci, USA 1992; 89: 7384-7388.
11. Suh O, Mettlin C, Petrelli NJ. Aspirin use, cancer and polyps of the large bowel. Cancer. 1993; 72: 1171-1177.
12. Peleg H, Maibach HT, Brown SH, Wilcox CM. Aspirin and non-steroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 1994; 154: 394-399.
13. Muscat JE, Stellman SD, Wynder EL. Non-steroidal antiinflammatory drugs and colorectal cancer. Cancer 1994; 74: 1847-1854.
14. La Vecchia C, Negri E, Franceschi S, et al. Aspirin and colorectal cancer. Br J Cancer 1997; 76: 675-677.
15. Rosenberg L, Palmer JR, Zauber AG, et al. A hypothesis:non-steroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991; 83: 355-358.
16. Fidler IJ. Molecular biology of cancer: invasion and metastasis. In Cancer: Principles and Practice of Oncology (5th edn) (Devita, V.T. et al., eds), pp 135-152, Lippincott-Raven, 1997.
17. Stetler-Stevenson WG, Hewitt R, et al. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol 1996; 7: 147-154.
18. Jones L, Ghaneh P, et al. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer. Ann New York Acad Sci 1999; 880: 288-307.
19. John A, Tuszynski G. The role of matrix metalloproteinase in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 2001; 7(1): 14-23.
20. Nguyen M, Arkell J, et al. Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol 2001; 33(10): 960-970.
21. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activator in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Analytical Biochemistry 1980; 102: 196-202.
22. Carson DA, Ribeiro JM. Apoptosis and disease. Lancet 1993; 341: 1251-1254.
23. Williams JT, Smith CA. Molecular regulation of apoptosis: genetic controls on cell death. Cell 1993; 74: 777-779.
24. Elder DJE, Halton DE, Hague A, Paraskeva C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)selective non-steroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res 1997; 3: 1679-1683.
25. Smith ML, Hawcroft G, Hull MA. The effect of nonsteroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur J Cancer 2000; 36: 664-674.
26. Chan AT. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet 2002; 3: 166-174.
27. Corley DA, Kerlikowske K, Verma R, Buffler P: Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003; 124(1): 47-56.
28. Johnson TW, Anderson K.E., Lazovich D, Folsom A.R: Association of Aspirin and Nonsteroidal Anti-inflammatory Drug Use with Breast Cancer. Cancer Epidemiol Biomarkers Prev 2002; 11(12): 1586-91.
29. Nithipatikom K, Isbell MA, Lindholm PF, et. al. Requirement of cyclooxygenase-2 expression and prostaglandins for human prostate cancer cell invasion. Clin Exp Metastasis 2002; 19(7): 593-601.
30. Rex DK. Screening for colon cancer and evaluation of chemoprevention with coxibs. J Pain Symptom Manage 2002; 23(4 Suppl): 41-50.
31. Ricciardiello L, Roda E, Bazzoli F. Chemoprevention in colorectal neoplasias: what is practical and feasible? Dig Dis 2002; 20(1): 70-2.
32. Lynch PM. COX-2 inhibition in clinical cancer prevention. Oncology (Huntingt) 2001; 15(3 Suppl 5): 21-6.
33. Thant AA, Serbulea M, et al: C-Ras is required for the activation of the matrix metalloproteinases by concanavalin A in 3Y1 cells. FEBS Letters 1997; 406: 28-30.
34. Eberhardt W, Schulze M, et al. Glucocorticoid-mediated suppression of Cytokine-induced matrix metalloproteinase-9 expression in Rat mesangial cells: involvement of nuclear factor-kappaB and Ets transcription factors. Mol Endocrinol 2002; 16(8): 1752-1766.
35. Pross C, Farooq MM, et al. Dexamethasone inhibits vascular smooth muscle cell migration via modulation of matrix metalloproteinase activity. J Surg Res 2002; 102(2): 57-62.
36. Sadowski T, Steinmeyer J. Effects of non-steroidal anti-inflammatory drugs and Dexamethasone on the activity and expression of matrix metalloproteinase-1, matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 by bovine articular chondrocytes. Osteoarthritis Cartilage 2001; 9(5): 407-415.